Follow
Mark J. Mulligan, MD, FIDSA
Mark J. Mulligan, MD, FIDSA
New York University Vaccine Center
Verified email at nyulangone.org
Title
Cited by
Cited by
Year
Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
EE Walsh, RW Frenck Jr, AR Falsey, N Kitchin, J Absalon, A Gurtman, ...
New England Journal of Medicine 383 (25), 2439-2450, 2020
28022020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
MJ Mulligan, KE Lyke, N Kitchin, J Absalon, A Gurtman, S Lockhart, ...
Nature 586 (7830), 589-593, 2020
18192020
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans
TD Querec, RS Akondy, EK Lee, W Cao, HI Nakaya, D Teuwen, A Pirani, ...
Nature immunology 10 (1), 116-125, 2009
12662009
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection
J Wrammert, D Koutsonanos, GM Li, S Edupuganti, J Sui, M Morrissey, ...
Journal of Experimental Medicine 208 (1), 181-193, 2011
9422011
Molecular signatures of antibody responses derived from a systems biology study of five human vaccines
S Li, N Rouphael, S Duraisingham, S Romero-Steiner, S Presnell, ...
Nature immunology 15 (2), 195-204, 2014
7702014
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine
SM Hammer, ME Sobieszczyk, H Janes, ST Karuna, MJ Mulligan, ...
New England Journal of Medicine 369 (22), 2083-2092, 2013
7212013
Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
AR Falsey, ME Sobieszczyk, I Hirsch, S Sproule, ML Robb, L Corey, ...
New England Journal of Medicine 385 (25), 2348-2360, 2021
6882021
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines
JD Miller, RG van der Most, RS Akondy, JT Glidewell, S Albott, ...
Immunity 28 (5), 710-722, 2008
6772008
Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus
L Priyamvada, KM Quicke, WH Hudson, N Onlamoon, J Sewatanon, ...
Proceedings of the National Academy of Sciences 113 (28), 7852-7857, 2016
6522016
Homologous and heterologous Covid-19 booster vaccinations
RL Atmar, KE Lyke, ME Deming, LA Jackson, AR Branche, HM El Sahly, ...
New England Journal of Medicine 386 (11), 1046-1057, 2022
5482022
Origin and differentiation of human memory CD8 T cells after vaccination
RS Akondy, M Fitch, S Edupuganti, S Yang, HT Kissick, KW Li, ...
Nature 552 (7685), 362-367, 2017
5382017
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells
GM Li, C Chiu, J Wrammert, M McCausland, SF Andrews, NY Zheng, ...
Proceedings of the National Academy of Sciences 109 (23), 9047-9052, 2012
4582012
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
BE Jones, PL Brown-Augsburger, KS Corbett, K Westendorf, J Davies, ...
Science translational medicine 13 (593), eabf1906, 2021
4412021
Magnitude of Functional CD8+ T-Cell Responses to the Gag Protein of Human Immunodeficiency Virus Type 1 Correlates Inversely with Viral Load in Plasma
BH Edwards, A Bansal, S Sabbaj, J Bakari, MJ Mulligan, PA Goepfert
Journal of virology 76 (5), 2298-2305, 2002
4412002
The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled …
NG Rouphael, M Paine, R Mosley, S Henry, DV McAllister, H Kalluri, ...
The Lancet 390 (10095), 649-658, 2017
4052017
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response
RS Akondy, ND Monson, JD Miller, S Edupuganti, D Teuwen, H Wu, ...
The Journal of Immunology 183 (12), 7919-7930, 2009
3812009
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
C Axfors, AM Schmitt, P Janiaud, J Van’t Hooft, S Abd-Elsalam, EF Abdo, ...
Nature communications 12 (1), 2349, 2021
3682021
Protection against vaginal SIV transmission with microencapsulated vaccine
PA Marx, RW Compans, A Gettie, JK Staas, RM Gilley, MJ Mulligan, ...
Science 260 (5112), 1323-1327, 1993
3341993
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
MR Gaudinski, KV Houser, KM Morabito, Z Hu, G Yamshchikov, ...
The Lancet 391 (10120), 552-562, 2018
3162018
Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures
HI Nakaya, T Hagan, SS Duraisingham, EK Lee, M Kwissa, N Rouphael, ...
Immunity 43 (6), 1186-1198, 2015
3162015
The system can't perform the operation now. Try again later.
Articles 1–20